|
NF-kappaB in pathogenesis and therapy of head and neck cancer
|
Research Initiative
|
FDA
|
NICHD
|
NF-kappaB in pathogenesis and therapy of head and neck cancer
|
|
NGSP (formerly the National Glycohemoglobin Standardization Program) (NGSP)
|
Resource Development
|
CDC
|
NIDDK, CC
|
The purpose of the NGSP (formerly the National Glycohemoglobin Standardization Program) is to standardize Hemoglobin A1c test results to those of the Diabetes Control and Complications Trial (DCCT) and the United Kingdom Prospective Diabetes Study (UKPDS), which established the direct relationships between HbA1c levels and outcome risks in patients with diabetes. NIDDK has provided funding for NGSP research initiatives, and NIDDK Extramural Program staff have served on committees.
|
|
NHAS Quality of Life Working Group
|
Committee, Work group, Advisory group, or Task Force
|
CDC, HRSA, SAMHSA, ACL
|
OD/DPCPSI/OAR, NIMH, NIAID
|
A working group of representatives from six federal agencies involved in developing and implementing the NHAS was tasked with carefully listening to community input and evaluating options for possible quality of life measures, data sources, and targets that could be adopted and implemented. As a result of their work and community input, the Office of National AIDS Policy ultimately adopted five indicators that reflect the multi-dimensional nature of quality of life among people with HIV. Indicators address self-rated health status, mental health, food insecurity, employment status, and unstable housing or homelessness.
|
|
NIA Confocal Imaging Facility
|
Research Initiative
|
FDA
|
NIA
|
NIA Confocal Imaging Facility
|
|
NIA IMPACT Collaboratory Transforming Dementia Care (IMPACT Collaboratory)
|
Research Initiative
|
CDC
|
NIA
|
The mission of the IMbedded Pragmatic Alzheimers disease (AD) and AD Related Dementias (AD/ADRD) Clinical Trials (IMPACT) Collaboratory is to build the nation’s capacity to conduct pragmatic clinical trials of interventions embedded within health care systems for people living with dementia and their care partners.
The IMPACT Collaboratory accomplishes this mission by: developing and disseminating best practice research methods; supporting the design and conduct of pragmatic trials, including pilot studies; building investigator capacity through training and knowledge generation; catalyzing collaboration among stakeholders, healthcare providers, and investigators; and ensuring the research includes culturally-tailored interventions and people from diverse and under-represented backgrounds.
|
|
NIAID/Armed Forces Radiobiology Research Institute (AFRRI) Research Coordination Team (RCT)
|
Committee, Work group, Advisory group, or Task Force
|
ASPR
|
NIAID
|
The Research Coordinating Team (RCT) has been successfully reestablished and will continue to meet quarterly in 2021. The purpose of the RCT is to discuss progress, resolve any concerns and to explore new areas of research to be conducted under the IAA.
|
|
NIAID/CDC Dual Use Research of Concern (DURC) Risk Mitigation Reviews
|
Committee, Work group, Advisory group, or Task Force
|
CDC
|
NIAID
|
The Centers for Disease Control and Prevention (CDC) Division of Select Agents and Toxins Division will provide technical assistance in evaluating the sufficiency of the biosecurity and/or biosafety measures incorporated into risk mitigation plans received from institutions, and cross-check risk mitigation plans and research conducted using select agents and toxins against information in the Federal Select Agent Program (FSAP) database.
|
|
NIAID/FDA/BARDA Meeting on Gastrointestinal Acute Radiation Syndrome (GI-ARS)
|
Meeting/ Workshop
|
FDA, ASPR
|
NIAID
|
The purpose of this meeting is to bring together medical countermeasures stakeholders such as academicians, industry, and funding and regulatory agencies to consider animal models and endpoints for radiation injuries to the gastrointestinal tract.
|
|
NIAID/NASA Medical Countermeasures Working Group
|
Committee, Work group, Advisory group, or Task Force
|
BARDA, FDA
|
NIAID, NCI, NHLBI
|
The purpose of this Working Group (WG) is to bring together experts in radiation countermeasures to look for complementary areas of research across agencies in the following areas: medical countermeasure selection, repurposing, research strategies, and animal models for select endpoints.
|
|
Nicotine Research Cigarettes (SPECTRUM)
|
Committee, Work group, Advisory group, or Task Force
|
FDA
|
NIDA
|
This partnership with the Food and Drug Administration (FDA) is for the production of research cigarettes.
|